DD23 Biomarker: A prospective clinical assessment in routine urinary cytology specimens from patients being monitored for TCC

Urologic Oncology

Volumn 7, Issue 5, 2002, Pages 185-190

  Sawczuk, Ihor S ^a,f   Pickens, Cynthia L ^b   Vasa, Usha R ^b   Ralph, David A ^c   Norris, Kathy A ^b   Miller, M Craig ^b   Ng, Angela Y ^d   Grossman, H Barton ^e   Veltri, Robert W ^b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b UroCor Incorporated   (United States)

^c Belenus Biomedical Inc   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bladder cancer; DD23 biomarker; Diagnostic cytology; Urine cellular biomarkers; Urine cytology

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY DD23; UNCLASSIFIED DRUG; ALKALINE PHOSPHATASE; AVIDIN; BIOLOGICAL MARKER; BIOTIN;

ADULT; AGED; ARTICLE; BLADDER BIOPSY; BLADDER CARCINOMA; CANCER DIAGNOSIS; CANCER GRADING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTOSCOPY; CYTOPATHOLOGY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; STAINING; TRANSITIONAL CELL CARCINOMA; URINE CYTOLOGY; BLADDER CANCER; FEULGEN STAINING; IMMUNOHISTOCHEMISTRY; MICTURITION; PAPANICOLAOU TEST; SENSITIVITY AND SPECIFICITY; UROTHELIUM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; BIOPSY; CARCINOMA, TRANSITIONAL CELL; CASE-CONTROL STUDIES; CYSTOSCOPY; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 0036765738     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-1439(02)00188-6     Document Type: Article

References (21)

1. Greenlee R.T., Hill-Harmon M.B.T., Murray, Thun M. Cancer Statistics, 2001. CA Cancer J Clin. 51:2001;15-36.
2. Mostofi F.K., Davis C.J., Sesterhenn I.A. Current understanding of pathology of bladder cancer and attendant problems. J Occup Med. 32:1990;793-796.
3. Droller M.J. Transitional cell carcinoma. upper tracts and bladder Walsh P., Gittes R., Perlmutter A., Stanley T. Campbell's urology., Vol 2. 4th Ed:1986;1343-1440 WB Saunders Co. Philadelphia, PA.
4. Murphy W.M., Soloway M.S., Jokkola A.F., Crabtree W.N., Ford K.S. Urinary cytology and bladder cancer. the cellular features of transitional cell neoplasms Cancer. 53:1984;1555-1565.
5. Raghaven D., Shioley W.U., Garnick M.B., Russell P.J., Richie J.P. Biology and management of bladder cancer. N Engl J Med. 322:1990;1129-1138.
6. Koss L.G. Diagnostic cytology and its histologic bases, vol. 2. 1979;Lippincott, Philadelphia. p. 767.
7. Murphy W.M. Current status of urinary cytology in the evaluation of bladder neoplasms. Human Path. 21:1990;886-896.
8. Badalament R.A., Hermansen D.K., Kimmel M., Gay H., Herr H., Fair W.et al. The sensitivity of bladder wash flow cytometry, bladder wash cytology, and voided cytology in the detection of bladder carcinoma. Cancer. 60(10):1987;1423-1426.
9. Slaton J.W., Dinney C.P.N., Veltri R.W., Miller M.C., Liebert M., O'Dowd G.J., Grossman H.B. DNA ploidy enhances the cytological prediction of recurrent transitional cell carcinoma of the bladder. J Urol. 158:1997;806-811.
10. Fradet Y., Cordon C.C. Critical appraisal of tumor markers in bladder cancer. Sem in Urol. 11(3):1993;145-153.
11. Burchardt M., Burchardt T., Shabsigh A., De La Taille A., Benson M.C., Sawczuk I. Current concepts in biomarker technology for bladder cancers. Clin Chem. 46:2000;595-605.
12. Shankey T.V., Jin J.-K., Dougherty S., Gandhi K., Pyle J. An overview of clinical applications for multi-parameter flow and image cytometry of urologic malignancies. Cancer Mol Biol. 1(1):1994;19-25.
13. Richman A., Mayne S., Jekel J., Albertsen P. Image analysis combined with visual cytology in the early detection of recurrent bladder carcinoma. Cancer. 82(9):1998;1738-1748.
14. Planz B., Striepecke E., Jakse G., Bocking A. Use of Lewis X antigen and deoxyribonucleic acid image cytometry to increase sensitivity of urinary cytology in transitional cell carcinoma of the bladder. J Urol. 159:1998;384-388.
15. Sidranski D., von Eschenbach A., Tsai Y.C.et al. Identification of p53 gene mutations in bladder cancers and urine samples. Science. 252:1991;706-708.
16. Krupski T., Moskaluk C., Boyd J.C., Theodorescu D. A prospective pilot evaluation of urinary and immunohistochemical markers as predictors of clinical stage of urothelial carcinoma of the bladder. BJU Int. 85:2000;1027-1032.
17. Mian C., Pycha A., Wiener H., Haitel A., Lodde M., Marberger M. Immuncyt® a new tool for detecting transitional cell cancer of the urinary tract J Urol. 161:1999;1486-1489.
18. Grossman H.B., Washington R.W., Carey T.E., Liebert M. Alterations in antigen expression in superficial bladder cancer. J Cell Biochem. 161:1992;63-68.
19. Grossman H.B., Liebert M., Flint A., Washington R.W. DD23. a monoclonal antibody reactive with bladder and breast cancer Proc Amer Assoc Can Research. 33:1992;1863A.
20. Bonner R.B., Liebert M., Hurst R.E., Grossman H.B., Bane B.L., Hemstreet G.P. III, the Marker Network for Bladder Cancer Characterization of the DD23 tumor-associated antigen for bladder cancer detection and recurrence monitoring. Cancer Epidemiology, Biomarker & Prevention. 5:1996;971-978.
21. Ang G.T., Marley G.M., Patton K.P., O'Dowd G.J., Veltri R.W. DD23 Biomarker enhances urinary cytopathologic detection of human bladder cancer. Am J Clin Pathol. 110:1998;523-524. (A39).